Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2832
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCAIRES, Inacelli Queiroz de Souza-
dc.contributor.authorCAIRES-LIMA, Rafael-
dc.contributor.authorCOLOMBO, Renata-
dc.contributor.authorRAMOS, Clarissa C. A.-
dc.contributor.authorMACHADO, Karime Kalil-
dc.contributor.authorSIQUEIRA, Sheila Aparecida Coelho-
dc.contributor.authorCARVALHO, Heloisa de Andrade-
dc.contributor.authorFUKUSHIMA, Julia Tizue-
dc.contributor.authorADRA, Thais Rodrigues-
dc.contributor.authorHOFF, Paulo M.-
dc.contributor.authorESTEVEZ-DIZ, Maria Del Pilar-
dc.date.accessioned2013-10-11T21:18:21Z-
dc.date.available2013-10-11T21:18:21Z-
dc.date.issued2012-
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, v.30, n.15, suppl.S, 2012-
dc.identifier.issn0732-183X-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2832-
dc.description.abstractBackground: CC is the leading cause of cancer death among women in developing countries. ERCC1 protein participates in DNA repair through the nucleotide excision repair pathway, involved in resistance to platinum-based chemotherapy. Its value as a predictive marker of tumor response to treatment, progression or death is still unknown. We evaluated ERCC1 protein expression and clinical variables as a predictive marker of progression-free survival (PFS) and overall survival (OS) in patients (pts) with CC submitted to CR. Methods: Retrospective data analysis of pts with histological diagnosis of CC, treated with CR between 2004-2009. Platinum-based chemotherapy was administered weekly (x6) concurrent to external beam radiotherapy (EBRT) to the pelvis (39.6 – 45.0 Gy), parametrial boost (14.0 – 20.0 Gy) when indicated and high-dose rate brachytherapy (HDR) (28.0 – 30.0 Gy). ERCC1 expression was assessed by immunohistochemistry (IHC). Results: We analyzed 75 pts, median age was 55 years (range 24-76), the performance status (PS) was 0 or 1 at baseline in 50 pts (66%) and 63 had squamous histology (84%). Thirty-two were stage IIB (43%) and 19 were IIIB (25%). Sixty-five patients received cisplatin 40mg/m2/w (87%) and 9, carboplatin AUC2/w (12%), median of 6 cycles (range 2-9). Median RT and HDR doses were 59.4 Gy (range 40.4 to 60.3) and 28.0 Gy (range 14.0 – 37.5), respectively. Thirty-two pts were available by ERCC1 IHC and all expressed the marker. Median PFS and OS were 35.5 (95% CI – 13.8 - 57.6) and 81 (95% CI- 21.2 - 140.8) months, respectively. In multivariate analysis, receiving < 6 chemotherapy cycles and baseline Hb <10.0 were correlated with disease progression and death, HR 0.302; p 0.011 (95% CI- 0.012-0.762) and HR 0.6; p 0.00 (95% CI- 0.474 – 0.760), respectively. PS at baseline did not correlate with PFS or OS, HR 0.985; p 0.614 (95% CI 0.930 – 1.044). Conclusions: In this population, since all pts expressed the protein, ERCC1 expression couldn't discriminate patients who most benefit from CR. Interestingly, a minimum of 6 chemotherapy cycles and a baseline Hb ≥ 10.0 seem to have a prognostic value.-
dc.language.isoeng-
dc.publisherAMER SOC CLINICAL ONCOLOGY-
dc.relation.ispartofJournal of Clinical Oncology-
dc.rightsrestrictedAccess-
dc.titleExpression of ERCC1 protein (excision repair cross complementing group 1) in patients with invasive carcinoma of the uterine cervix (CC) undergoing definitive chemoradiation (CR)-
dc.typeconferenceObject-
dc.rights.holderCopyright AMER SOC CLINICAL ONCOLOGY-
dc.description.conferencedateJUN 01-06, 2012-
dc.description.conferencelocalChicago - IL, EUA-
dc.description.conferencename48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)-
dc.subject.wosOncology-
dc.type.categorymeeting abstract-
dc.type.versionpublishedVersion-
hcfmusp.description.issue15-
hcfmusp.description.issuesuppl S-
hcfmusp.description.volume30-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000318009803439-
hcfmusp.publisher.cityALEXANDRIA-
hcfmusp.publisher.countryUSA-
dc.description.indexMEDLINE-
Appears in Collections:

Comunicações em Eventos - FM/MDR
Departamento de Radiologia - FM/MDR

Comunicações em Eventos - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - HC/InRad
Instituto de Radiologia - HC/InRad

Comunicações em Eventos - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática

Comunicações em Eventos - LIM/24
LIM/24 - Laboratório de Oncologia Experimental


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.